161 related articles for article (PubMed ID: 23400406)
21. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
Nicolle E; Boccard J; Guilet D; Dijoux-Franca MG; Zelefac F; Macalou S; Grosselin J; Schmidt J; Carrupt PA; Di Pietro A; Boumendjel A
Eur J Pharm Sci; 2009 Aug; 38(1):39-46. PubMed ID: 19501160
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
24. Designing potent inhibitors against the multidrug resistance P-glycoprotein.
Mahmud S; Islam MJ; Parves MR; Khan MA; Tabussum L; Ahmed S; Ali MA; Fakayode SO; Halim MA
J Biomol Struct Dyn; 2022; 40(19):9403-9415. PubMed ID: 34060432
[TBL] [Abstract][Full Text] [Related]
25. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines.
Hiessböck R; Wolf C; Richter E; Hitzler M; Chiba P; Kratzel M; Ecker G
J Med Chem; 1999 Jun; 42(11):1921-6. PubMed ID: 10354400
[TBL] [Abstract][Full Text] [Related]
27. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
28. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
[TBL] [Abstract][Full Text] [Related]
29. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
30. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
31. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance.
Kaiser D; Smiesko M; Kopp S; Chiba P; Ecker GF
Med Chem; 2005 Sep; 1(5):431-44. PubMed ID: 16787327
[TBL] [Abstract][Full Text] [Related]
32. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia.
Damiani D; Michelutti A; Michieli M; Masolini P; Stocchi R; Geromin A; Ermacora A; Russo D; Fanin R; Baccarani M
Br J Haematol; 2002 Mar; 116(3):519-27. PubMed ID: 11849207
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Structure⁻Activity Relationships for the Flavonoid-Mediated Inhibition of P-Glycoprotein in KB/MDR1 Cells.
Xia M; Fang Y; Cao W; Liang F; Pan S; Xu X
Molecules; 2019 Apr; 24(9):. PubMed ID: 31035631
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
36. A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance.
Tmej C; Chiba P; Huber M; Richter E; Hitzler M; Schaper KJ; Ecker G
Arch Pharm (Weinheim); 1998; 331(7-8):233-40. PubMed ID: 9747179
[TBL] [Abstract][Full Text] [Related]
37. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Cianchetta G; Singleton RW; Zhang M; Wildgoose M; Giesing D; Fravolini A; Cruciani G; Vaz RJ
J Med Chem; 2005 Apr; 48(8):2927-35. PubMed ID: 15828831
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells.
Kitagawa S; Nabekura T; Takahashi T; Nakamura Y; Sakamoto H; Tano H; Hirai M; Tsukahara G
Biol Pharm Bull; 2005 Dec; 28(12):2274-8. PubMed ID: 16327165
[TBL] [Abstract][Full Text] [Related]
39. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.
Fu D; Roufogalis BD
Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1543-52. PubMed ID: 17122416
[TBL] [Abstract][Full Text] [Related]
40. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
